Uma acção que entrou hoje no meu porfolio e que merece...
albrib Escreveu:Curis says drug fails in colon cancer study
Curis says drug candidate fails to meet treatment goal in midstage colon cancer study
ap
On Wednesday June 16, 2010, 9:07 am
CAMBRIDGE, Mass. (AP) -- Drug developer Curis Inc. said a potential colon cancer treatment failed to meet its goal in a midstage study.
The study is being conducted by Curis' partner Roche and that company's Genentech unit. It focused on combining Avastin and chemotherapy with the experimental GDC-0449 as an initial treatment for colon cancer. The combination failed to stem disease progression when compared with patients taking the current standard of care treatment.
"Despite these disappointing results in metastatic colorectal (colon) cancer, we remain encouraged that Genentech and Roche's clinical development of GDC-0449 in other cancers continues to make good progress," said Curis President and CEO Dan Passeri.
The colon cancer study involved 195 people.
http://finance.yahoo.com/news/Curis-say ... l?x=0&.v=1
A curis está a realizar mais do que 20 ensaios clinicos diferentes! basta um dar certo para a cotação disparar fortemente.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Entrada Longa na AFFY , parece-me barata em termos fundamentais este titulo.
- Anexos
-
- sc.png (57.49 KiB) Visualizado 1471 vezes
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
albrib Escreveu:Curis says drug fails in colon cancer study
Curis says drug candidate fails to meet treatment goal in midstage colon cancer study
ap
On Wednesday June 16, 2010, 9:07 am
CAMBRIDGE, Mass. (AP) -- Drug developer Curis Inc. said a potential colon cancer treatment failed to meet its goal in a midstage study.
The study is being conducted by Curis' partner Roche and that company's Genentech unit. It focused on combining Avastin and chemotherapy with the experimental GDC-0449 as an initial treatment for colon cancer. The combination failed to stem disease progression when compared with patients taking the current standard of care treatment.
"Despite these disappointing results in metastatic colorectal (colon) cancer, we remain encouraged that Genentech and Roche's clinical development of GDC-0449 in other cancers continues to make good progress," said Curis President and CEO Dan Passeri.
The colon cancer study involved 195 people.
http://finance.yahoo.com/news/Curis-say ... l?x=0&.v=1
Obrigado
Só espero que não aconteça o mesmo na GNBT
- Mensagens: 331
- Registado: 7/12/2007 0:29
Curis says drug fails in colon cancer study
Curis says drug candidate fails to meet treatment goal in midstage colon cancer study
ap
On Wednesday June 16, 2010, 9:07 am
CAMBRIDGE, Mass. (AP) -- Drug developer Curis Inc. said a potential colon cancer treatment failed to meet its goal in a midstage study.
The study is being conducted by Curis' partner Roche and that company's Genentech unit. It focused on combining Avastin and chemotherapy with the experimental GDC-0449 as an initial treatment for colon cancer. The combination failed to stem disease progression when compared with patients taking the current standard of care treatment.
"Despite these disappointing results in metastatic colorectal (colon) cancer, we remain encouraged that Genentech and Roche's clinical development of GDC-0449 in other cancers continues to make good progress," said Curis President and CEO Dan Passeri.
The colon cancer study involved 195 people.
http://finance.yahoo.com/news/Curis-say ... l?x=0&.v=1
Curis says drug candidate fails to meet treatment goal in midstage colon cancer study
ap
On Wednesday June 16, 2010, 9:07 am
CAMBRIDGE, Mass. (AP) -- Drug developer Curis Inc. said a potential colon cancer treatment failed to meet its goal in a midstage study.
The study is being conducted by Curis' partner Roche and that company's Genentech unit. It focused on combining Avastin and chemotherapy with the experimental GDC-0449 as an initial treatment for colon cancer. The combination failed to stem disease progression when compared with patients taking the current standard of care treatment.
"Despite these disappointing results in metastatic colorectal (colon) cancer, we remain encouraged that Genentech and Roche's clinical development of GDC-0449 in other cancers continues to make good progress," said Curis President and CEO Dan Passeri.
The colon cancer study involved 195 people.
http://finance.yahoo.com/news/Curis-say ... l?x=0&.v=1
-
- Mensagens: 360
- Registado: 17/12/2008 12:33
- Localização: Açores
Boas!
A Curis tem andado meio esqueçida neste forúm. Contudo, nas actuais condições de mercado tem tido um comportamneto muito positivo.
http://finance.yahoo.com/q?s=CRIS
Os Fundos andam a acumular forte e feio:
http://www.mffais.com/cris
devido ao pipeline desta empresa e ao aumento crescente da posição dos fundos, acredito que a médio prazo podem acontecer retornos interessantes.
A Curis tem andado meio esqueçida neste forúm. Contudo, nas actuais condições de mercado tem tido um comportamneto muito positivo.
http://finance.yahoo.com/q?s=CRIS
Os Fundos andam a acumular forte e feio:
http://www.mffais.com/cris
devido ao pipeline desta empresa e ao aumento crescente da posição dos fundos, acredito que a médio prazo podem acontecer retornos interessantes.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
karpediem Escreveu:Ulisses Pereira Escreveu:AC, a mim não me levou a achar nada, até porque nem sigo a acção. Mas como moderador, o meu papel é pedir aos participantes que justifiquem as suas opiniões.
Deixa-me, no entanto, dizer que distinguir se é acumulação ou distribuição é das coisas mais difíceis nos mercados financeiros...
Um abraço,
Ulisses
Ulisses,
E como é que se pode analisar se é uma distribuição ou acumulação ? que indicadores pudemos ver ?
Obrigado
Ricardo
Estou convencido que a distribuição é quando o titulo prepara-se para cair e acumulação é quando prepara-se para subir.
Mas posso estar errado
-
- Mensagens: 2543
- Registado: 21/12/2009 18:46
- Localização: Faro
Boas!
não existe outra forma de saber as posições dos fundos sem ser pelo site: http://www.mffais.com/cris ???
pois, provavelmente ainda vai demorar alguns dias / semanas a actualizar! e gostava de ter acesso a essa informação o mais rápido possível!
a questão que se coloca é a seguinte:
se toda a análise que tenho efectuada sobre esta acção está certa podemos estar perante um movimento explosivo da Curis nos proximos meses, pois o numero de acções disponíveis para negociação vai ser reduzido! não se esqueçam que a Curis tem 14 ensaios clinicos em desenvolvimento e basta que um ou dois se revelem positivos para ela explodir. Além disso a Curis esta a desenvolver uma nova droga....ah! e os pagamentos da Diopharm....ah! e os rumores da Roche!...ah!em 30 de setembro um fundo tinha 20% da Roche! devem gostar bastante dela....
se estiver errado, ...azar!!!! neste momento a cotação está a 3,53 e desde que a Curis não feche abaixo dos 3,30 não fico preocupado. Caso isso aconteça admito deixar a acção. No entanto acredito, se o padrão das ultimas subidas voltar a acontecer, que a Curis vai atingir os 4 dolares nas proximas sessões.
não existe outra forma de saber as posições dos fundos sem ser pelo site: http://www.mffais.com/cris ???
pois, provavelmente ainda vai demorar alguns dias / semanas a actualizar! e gostava de ter acesso a essa informação o mais rápido possível!
a questão que se coloca é a seguinte:
se toda a análise que tenho efectuada sobre esta acção está certa
podemos estar perante um movimento explosivo da Curis nos proximos meses, pois o numero de acções disponíveis para negociação vai ser reduzido! não se esqueçam que a Curis tem 14 ensaios clinicos em desenvolvimento e basta que um ou dois se revelem positivos para ela explodir. Além disso a Curis esta a desenvolver uma nova droga....ah! e os pagamentos da Diopharm....ah! e os rumores da Roche!...ah!em 30 de setembro um fundo tinha 20% da Roche! devem gostar bastante dela....
se estiver errado, ...azar!!!! neste momento a cotação está a 3,53 e desde que a Curis não feche abaixo dos 3,30 não fico preocupado. Caso isso aconteça admito deixar a acção. No entanto acredito, se o padrão das ultimas subidas voltar a acontecer, que a Curis vai atingir os 4 dolares nas proximas sessões.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Ulisses Pereira Escreveu:Na minha opinião, não há qualquer indicador fiável nessa matéria.
Um abraço,
Ulisses
Então usas a tua experiencia para saberes ?
Ou não é importante para as tuas decisões de investimento ?
Carpe diem quam minimum credula postero
-
- Mensagens: 303
- Registado: 28/4/2009 12:49
- Localização: 16
Ulisses Pereira Escreveu:AC, a mim não me levou a achar nada, até porque nem sigo a acção. Mas como moderador, o meu papel é pedir aos participantes que justifiquem as suas opiniões.
Deixa-me, no entanto, dizer que distinguir se é acumulação ou distribuição é das coisas mais difíceis nos mercados financeiros...
Um abraço,
Ulisses
Ulisses,
E como é que se pode analisar se é uma distribuição ou acumulação ? que indicadores pudemos ver ?
Obrigado
Ricardo
Carpe diem quam minimum credula postero
-
- Mensagens: 303
- Registado: 28/4/2009 12:49
- Localização: 16
Bom dia a todos!
brevemente vamos saber toda a verdade sobre a CURIS!!
Aguardo com expectativa a actualização da informação sobre as compras dos fundos (ver http://www.mffais.com/cris)
Estou ansioso para saber o numero de acções que a Arnhold And S Bleichroeder Advisers Llc tem em carteira!!!!
Dependendo desta informação! admito repensar a minha estratégia!
Cumprimentos
brevemente vamos saber toda a verdade sobre a CURIS!!
Aguardo com expectativa a actualização da informação sobre as compras dos fundos (ver http://www.mffais.com/cris)
Estou ansioso para saber o numero de acções que a Arnhold And S Bleichroeder Advisers Llc tem em carteira!!!!
Dependendo desta informação! admito repensar a minha estratégia!
Cumprimentos
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
a Curis está lá!!!!!!!!!!
BIO Announces Initial Companies Selected to Present at the Twelfth Annual BIO® CEO & Investor Conference
Conference Will Be Held February 8-9 at the Waldorf=Astoria Hotel New York City
BIO CEO & Investor Conference
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
“Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Over 120 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org.
This year’s presenting companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top-tier investment firms and CEOs from leading biotech companies:
Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw, LLC
Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman & Renshaw, LLC
Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
J. Donald deBethizy, Ph.D.; President & CEO, Targacept
David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio Manager, Fred Alger Management, Inc.
Howard Furst, M.D.; Partner, Deerfield Management
Cory W. Kasimov; Vice President , J.P Morgan
David Kroin; Managing Director, Great Point Partners, LLC
Kelly Lisbakken; Vice President, Investment Banking, Wedbush PacGrow Life Sciences
Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology Analyst, Deutsche Bank AG
Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
“The BIO CEO & Investor Conference will showcase companies representing the industry’s most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Now in its twelfth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry.
This year’s meeting will feature issue-oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. Access to top investors and industry executives will also be powered by BIO One-on-One Partnering, BIO’s interactive online system that allows you to intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Twelfth Annual BIO CEO & Investor Conference:
4SC AG (VSC)
Acorda Therapeutics Inc. (ACOR)
Actelion Ltd. (ATLN)
Acucela Inc. (Private)
Addex Pharmaceuticals S.A. (ADXN)
Affymax Inc. (AFFY)
Alexza Pharmaceuticals Inc. (ALXA)
Alkermes Inc. (ALKS)
Allon Therapeutics Inc. (NPCUF)
Allos Therapeutics Inc. (ALTH)
Alnylam Pharmaceuticals Inc. (ALNY)
Amarin Corp. PLC (AMRN)
Amsterdam Molecular Therapeutics Holding N.V. (AMT)
Anadys Pharmaceuticals Inc. (ANDS)
ARCA biopharma, Inc. (ABIO)
Ardea Biosciences Inc. (RDEA)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
Bavarian Nordic A/S (BAVA)
BioCryst Pharmaceuticals Inc. (BCRX)
BioMarin Pharmaceutical Inc. (BMRN)
Bionomics Ltd. (BNO)
BioSante Pharmaceuticals Inc. (BPAX)
BioTie Therapies Oyj (BTH1V)
Cell Therapeutics Inc. (CTIC)
Cellectis S.A. (ALCLS)
CEL-SCI Corp. (CVM)
CERUS CORP (CERS)
Chelsea Therapeutics International Ltd. (CHTP)
ChemGenex Pharmaceuticals Ltd. (CXS)
Cleveland BioLabs Inc. (CBLI)
CombinatoRx Inc. (CRXX)
Curis Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cytokinetics Inc. (CYTK)
DepoMed Inc. (DEPO)
Diamyd Medical AB (DMYDF)
Discovery Laboratories Inc. (DSCO)
DUSA (DUSA)
Dyax Corp. (DYAX)
Elan Pharmaceuticals (Private)
EMISPHERE TECHNOLOGIES INC (EMIS)
EpiCept Corporation (EPCT)
Exelixis Inc. (EXEL)
Genta Inc. (GETA)
GenVec Inc. (GNVC)
GeoVax Labs Inc. (GOVX)
Geron Corp. (GERN)
Gilead Sciences Inc. (GILD)
GlobeImmune (Private)
Hana Biosciences, Inc (HNAB)
Human Genome Sciences Inc. (HGSI)
Icagen, Inc. (ICGN)
Idenix Pharmaceuticals Inc. (IDIX)
Idera Pharmaceuticals Inc. (IDRA)
Immunogen Inc. (IMGN)
Immunovaccine Inc. (IMV)
Inovio Biomedical Corp. (INO)
Ista Pharmaceuticals Inc. (ISTA)
Javelin Pharmaceuticals, Inc. (JAV)
Lexicon Pharmaceuticals Inc. (LXRX)
Ligand Pharmaceuticals Inc. (LGND)
MannKind Corp. (MNKD)
MDRNA Inc. (MRNA)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Molecular Insight Pharmaceuticals Inc. (MIPI)
MolMed S.p.A. (MLM)
Momenta Pharmaceuticals Inc. (MNTA)
Neuralstem Inc. (CUR)
NeurogesX Inc. (NGSX)
NexMed Inc. (NEXM)
NicOx S.A. (COX)
Nile Therapeutics Inc. (NLTX)
NovaBay Pharmaceuticals Inc. (NBY)
Novavax Inc. (NVX)
NPS Pharmaceuticals Inc. (NPSP)
Oncolytics Biotech Inc. (ONC)
Oncothyreon Inc. (ONTY)
Orexigen Therapeutics Inc. (OREX)
Paion AG (PA8)
PDL BioPharma Inc. (PDLI)
Pharmacyclics Inc. (PCYC)
Poniard Pharmaceuticals Inc. (PARD)
Prolor Biotech Inc. (PBTH)
Repligen Corp. (RGEN)
Resverlogix Corp. (RVX)
Rexahn Pharmaceuticals Inc. (RNN)
Rigel Pharmaceuticals Inc. (RIGL)
RXI Pharmaceuticals Corp. (RXII)
Sangamo BioSciences Inc. (SGMO)
Soligenix, Inc. (SNGX)
Somaxon Pharmaceuticals Inc. (SOMX)
Spectrum Pharmaceuticals Inc. (SPPI)
SuperGen Inc. (SUPG)
SYGNIS Pharma AG (LIO)
Targacept Inc. (TRGT)
Transgenomic Inc. (TBIO)
Vertex Pharmaceuticals Inc. (VRTX)
VirtualScopics Inc. (VSCP)
VIVUS Inc. (VVUS)
XOMA Ltd. (XOMA)
YM BioSciences Inc. (YM)
Conference Will Be Held February 8-9 at the Waldorf=Astoria Hotel New York City
BIO CEO & Investor Conference
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a rigorous screening process and were evaluated based on several criteria, including their potential to deliver on near-term clinical catalysts and accomplishments across major therapeutic markets and areas of unmet medical need.
“Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Over 120 presenting companies will be selected and posted on the conference website on a rolling basis. To view the latest list, please visit http://ceo.bio.org.
This year’s presenting companies were chosen using metrics developed by BIO’s internal Industry Analysis team and were further vetted by an Advisory Committee, comprised of members from top-tier investment firms and CEOs from leading biotech companies:
Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw, LLC
Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman & Renshaw, LLC
Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
J. Donald deBethizy, Ph.D.; President & CEO, Targacept
David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio Manager, Fred Alger Management, Inc.
Howard Furst, M.D.; Partner, Deerfield Management
Cory W. Kasimov; Vice President , J.P Morgan
David Kroin; Managing Director, Great Point Partners, LLC
Kelly Lisbakken; Vice President, Investment Banking, Wedbush PacGrow Life Sciences
Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology Analyst, Deutsche Bank AG
Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
“The BIO CEO & Investor Conference will showcase companies representing the industry’s most promising investment opportunities with late-stage clinical pipelines, well-established business strategies or strong M&A and partnering potential,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Selected companies are also distinguished by significant opportunities for value creation with near-term clinical, regulatory and corporate catalysts that will continue to foster the growth of our industry in the new decade.”
Now in its twelfth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior executives from leading global pharmaceutical and biotechnology companies have the opportunity to shape the future investment landscape of the biotechnology industry.
This year’s meeting will feature issue-oriented plenary sessions, company presentations and educational sessions focused on business trends and hot therapeutic areas in life sciences. Access to top investors and industry executives will also be powered by BIO One-on-One Partnering, BIO’s interactive online system that allows you to intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit http://ceo.bio.org. Registration is complimentary for qualified investors and credentialed members of the media.
The following companies will present at the Twelfth Annual BIO CEO & Investor Conference:
4SC AG (VSC)
Acorda Therapeutics Inc. (ACOR)
Actelion Ltd. (ATLN)
Acucela Inc. (Private)
Addex Pharmaceuticals S.A. (ADXN)
Affymax Inc. (AFFY)
Alexza Pharmaceuticals Inc. (ALXA)
Alkermes Inc. (ALKS)
Allon Therapeutics Inc. (NPCUF)
Allos Therapeutics Inc. (ALTH)
Alnylam Pharmaceuticals Inc. (ALNY)
Amarin Corp. PLC (AMRN)
Amsterdam Molecular Therapeutics Holding N.V. (AMT)
Anadys Pharmaceuticals Inc. (ANDS)
ARCA biopharma, Inc. (ABIO)
Ardea Biosciences Inc. (RDEA)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
Bavarian Nordic A/S (BAVA)
BioCryst Pharmaceuticals Inc. (BCRX)
BioMarin Pharmaceutical Inc. (BMRN)
Bionomics Ltd. (BNO)
BioSante Pharmaceuticals Inc. (BPAX)
BioTie Therapies Oyj (BTH1V)
Cell Therapeutics Inc. (CTIC)
Cellectis S.A. (ALCLS)
CEL-SCI Corp. (CVM)
CERUS CORP (CERS)
Chelsea Therapeutics International Ltd. (CHTP)
ChemGenex Pharmaceuticals Ltd. (CXS)
Cleveland BioLabs Inc. (CBLI)
CombinatoRx Inc. (CRXX)
Curis Inc. (CRIS)
Cyclacel Pharmaceuticals Inc. (CYCC)
Cytokinetics Inc. (CYTK)
DepoMed Inc. (DEPO)
Diamyd Medical AB (DMYDF)
Discovery Laboratories Inc. (DSCO)
DUSA (DUSA)
Dyax Corp. (DYAX)
Elan Pharmaceuticals (Private)
EMISPHERE TECHNOLOGIES INC (EMIS)
EpiCept Corporation (EPCT)
Exelixis Inc. (EXEL)
Genta Inc. (GETA)
GenVec Inc. (GNVC)
GeoVax Labs Inc. (GOVX)
Geron Corp. (GERN)
Gilead Sciences Inc. (GILD)
GlobeImmune (Private)
Hana Biosciences, Inc (HNAB)
Human Genome Sciences Inc. (HGSI)
Icagen, Inc. (ICGN)
Idenix Pharmaceuticals Inc. (IDIX)
Idera Pharmaceuticals Inc. (IDRA)
Immunogen Inc. (IMGN)
Immunovaccine Inc. (IMV)
Inovio Biomedical Corp. (INO)
Ista Pharmaceuticals Inc. (ISTA)
Javelin Pharmaceuticals, Inc. (JAV)
Lexicon Pharmaceuticals Inc. (LXRX)
Ligand Pharmaceuticals Inc. (LGND)
MannKind Corp. (MNKD)
MDRNA Inc. (MRNA)
Medivation Inc. (MDVN)
Micromet Inc. (MITI)
Molecular Insight Pharmaceuticals Inc. (MIPI)
MolMed S.p.A. (MLM)
Momenta Pharmaceuticals Inc. (MNTA)
Neuralstem Inc. (CUR)
NeurogesX Inc. (NGSX)
NexMed Inc. (NEXM)
NicOx S.A. (COX)
Nile Therapeutics Inc. (NLTX)
NovaBay Pharmaceuticals Inc. (NBY)
Novavax Inc. (NVX)
NPS Pharmaceuticals Inc. (NPSP)
Oncolytics Biotech Inc. (ONC)
Oncothyreon Inc. (ONTY)
Orexigen Therapeutics Inc. (OREX)
Paion AG (PA8)
PDL BioPharma Inc. (PDLI)
Pharmacyclics Inc. (PCYC)
Poniard Pharmaceuticals Inc. (PARD)
Prolor Biotech Inc. (PBTH)
Repligen Corp. (RGEN)
Resverlogix Corp. (RVX)
Rexahn Pharmaceuticals Inc. (RNN)
Rigel Pharmaceuticals Inc. (RIGL)
RXI Pharmaceuticals Corp. (RXII)
Sangamo BioSciences Inc. (SGMO)
Soligenix, Inc. (SNGX)
Somaxon Pharmaceuticals Inc. (SOMX)
Spectrum Pharmaceuticals Inc. (SPPI)
SuperGen Inc. (SUPG)
SYGNIS Pharma AG (LIO)
Targacept Inc. (TRGT)
Transgenomic Inc. (TBIO)
Vertex Pharmaceuticals Inc. (VRTX)
VirtualScopics Inc. (VSCP)
VIVUS Inc. (VVUS)
XOMA Ltd. (XOMA)
YM BioSciences Inc. (YM)
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
AC, a mim não me levou a achar nada, até porque nem sigo a acção. Mas como moderador, o meu papel é pedir aos participantes que justifiquem as suas opiniões.
Deixa-me, no entanto, dizer que distinguir se é acumulação ou distribuição é das coisas mais difíceis nos mercados financeiros...
Um abraço,
Ulisses
Deixa-me, no entanto, dizer que distinguir se é acumulação ou distribuição é das coisas mais difíceis nos mercados financeiros...
Um abraço,
Ulisses
-
- Administrador Fórum
- Mensagens: 31013
- Registado: 29/10/2002 4:04
- Localização: Aveiro
Ulisses Pereira Escreveu:Pedro, porquê acumulação e não distribuição?
Um abraço,
Ulisses
Porque?
1 - quedas com baixo volume e subidas com bom volume
2 - o esquema de trading. tenho seguido atentamente os cofres e tenho a sensação que estão a encher o "saco" com acções da Curis
Atenção:
se hoje a Curis quebrar os 3,68 temos o caminho aberto para os 4 doláres!
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Ulisses Pereira Escreveu:Pedro, porquê acumulação e não distribuição?
Um abraço,
Ulisses
Tou fora da CRIS, no entanto julgo que a tendência e os sinais estão claramnete favoráveis aos Touros. Pelo gráfico nenhum indicador me dá sinal de distribuição, mas tudo é possivel.....
Ulisses, o que te levou a supor distribuição ?
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
Quem está ligado: